Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that Sarah Cannon Research Institute (SCRI) has joined the Strata Precision Indications for Approved THerapies (Strata PATH™) trial. Researchers will enroll patients at eight SCRI-affiliated sites including:

• Florida Cancer Specialists (4 sites)
• Genesis Cancer and Blood Institute, Hot Springs, AR
• Hematology Oncology Clinic, Baton Rouge, LA
• Tennessee Oncology, Chattanooga, TN
• Zangmeister Cancer Center, Columbus, OH

Strata PATH is a prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations. A range of therapeutic classes will be evaluated across tumor types, including targeted therapies, antibody-drug conjugates, immunotherapies, and angiogenesis inhibitors.

 “Strata is thrilled to partner with SCRI to bring new advances and increased options to patients with both late-stage and early-stage cancer,” said Dan Rhodes, Ph.D., co-founder and Chief Executive Officer, Strata Oncology. “In the Strata PATH trial, we are investigating how our innovative molecular profiling platform and our novel quantitative RNA algorithms can be used to optimize and expand the use of cancer treatments across therapeutic classes. Partnering with leading organizations like SCRI is integral to expanding the reach of this transformative clinical trial.”

“The Strata PATH study aligns with our mission to advance cancer therapies and offer personalized cancer care close to home,” said Andrew McKenzie, Vice President, Personalized Medicine, Sarah Cannon Research Institute. “We look forward to leveraging our cutting-edge patient identification strategies to expand access to the latest therapies through the Strata PATH clinical trial.”

Patients interested in learning more about the Strata PATH trial can visit ClinicalTrials.gov and search for the Strata PATH Trial identifier: NCT05097599.